<qa>  What is the treatment use protocol used to provide eligible lung transplant recipients early access to CIS inCurrently there are no approved therapies for lung transplant recipients in the United States US. Treatment with CIS following lung transplantation has previously been demonstrated to result in a clinically meaningful improvement in survival and chronic rejection-free survival compared to placebo, but additional data supporting its use is needed prior to Food and Drug Administration FDA approval. This treatment use protocol is a mechanism for providing eligible lung transplant recipients early access to CIS in advance of FDA approval. 